跳至主要内容
临床试验/NCT05397652
NCT05397652已完成4 期

Effect of Intravenously Administered Tranexamic Acid on Intraoperative Visual Clarity, Perioperative Blood Loss and Early Postoperative Outcomes in Shoulder Arthroscopy Performed in the Beach Chair Position: A Randomized Controlled Trial

Nikola Matejcic1 个研究点 分布在 1 个国家目标入组 121 人开始时间: 2021年5月24日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
121
试验地点
1
主要终点
Visual Clarity on Endoscope Screen During Shoulder Arthroscopy (Intraoperative)

研究概览

简要总结

Shoulder arthroscopy offers numerous advantages and has led to a continuous increase in procedural complexity. Adequate intraoperative visual clarity is essential for successful performance of the procedure and is primarily dependent on effective hemorrhage control.The aim of this prospective, double-blind, randomized controlled study is to evaluate the effect of intravenously administered tranexamic acid (TXA) on intraoperative visual clarity, perioperative blood loss, procedure duration, and early postoperative outcomes in patients undergoing shoulder arthroscopy in the beach chair position, an area for which limited data are currently available in the literature. In both the experimental and control groups, hemoglobin levels are measured in the irrigation fluid and in patients' blood samples obtained before and after surgery. Additional outcomes include intraoperative visual clarity, duration of the procedure, postoperative shoulder swelling, postoperative pain intensity, and analgesic consumption.This study applies established scientific methods to determine whether there is a justified basis for the introduction of TXA into routine clinical practice for shoulder arthroscopy.

详细描述

All surgical procedures will be performed at the University orthopaedic and trauma hospital Lovran, Croatia. Upon arrival at the hospital, the patient's body weight and height will be recorded. One day before the procedure, the patient will have blood taken from a vein and a complete blood count will be analyzed. Body weight and height were also recorded, and body mass index was calculated. Before the procedure, a physiotherapist measured the initial shoulder circumference in centimeters at three standardized measurement points: axilla-acromion (point A), axilla-deltoid (point B), and 10 cm above the olecranon (point C). The circumferences were documented on a standardized data collection form. Immediately before the procedure, patients will receive regional infiltrative (interscalene block) and general anesthesia with airway protection by endotracheal tube or laryngeal mask. Patients in the experimental group will receive 1 g of TXA in 100 ml of sterile saline IV 10 min before the start of the procedure, while patients in the control group will receive only sterile saline. The position of the patients will be beach chair with the head in the protective helmet and the arm in the front traction of 2,5 kg. All patients will be operated on by the same surgeon (NM) with the usual equipment: 4 mm 30° arthroscopic lens, arthroscopic pump basically set to 50 mmHg with the possibility of pulse increase of pressure by 20 mmHg for 2 min as needed, radiofrequency ablator and arthroscopic shaver system. Rotator cuff tendon repair will be performed using suture anchors as the primary procedure in all patients. If needed, additional procedures will be carried out, including glenohumeral (GH) stabilization by capsulolabral plication, labral repair, and long head of the biceps brachii (LHBB) tenodesis using the same implants. In cases of more severe damage or inflammation, LHBB tenotomy will be performed instead. Acromioclavicular (AC) joint repositioning and vertical stabilization will be performed using a suspensory fixation system with titanium buttons and synthetic tapes.

Other possible procedures include subacromial and subcoracoid bursectomy with soft tissue release, acromioplasty, tuberoplasty, AC joint resection, capsulotomy, synovectomy, microfracture (MFX), paralabral cyst evacuation, tendon drilling, removal of calcifications or implants, and tissue or implant sampling for histological and microbiological analysis. At the beginning of surgery and every 15 minutes thereafter, the surgeon will assess arthroscopic visibility using a Visual Analogue Scale (VAS-V) ranging from 0 (worst) to 10 (best), while being blinded to TXA allocation. Simultaneously, the endoscopic screen will be photographed with a 40 MP camera. Scores will be recorded, and images stored. Screen photos will be presented after surgery to three independent surgeons with experience in arthroscopy on visual clarity estimation (VAS range 0-10). Intraoperative data will include the number and extent of tendon lesions, presence of synovitis, operative time, mean arterial pressure (MAP), number of irrigation pressure boosts, and fluid inflow/outflow volumes. All procedures and implants will be documented. Any intraoperative complications (e.g., camera fogging, implant/instrument failure) will be noted. All administered crystalloids/colloids will be listed. Irrigation waste fluid will be collected and homogenized, and a 20 mL sample will be taken for analysis. Hemoglobin concentration will then be determined in the homogenized sample using spectrophotometry (Cripps method; University of Rijeka, Medical Faculty; Varian Cary 100 Bio, 190-900 nm, resolution ≤ 0.189 nm, wavelength accuracy ± 0.02-0.04 nm). On the first day after the surgery, the shoulder circumference will be measured at 3 typical sites and the level of pain will be noted (VAS range 0 no pain -10 the strongest pain). On the second day, the shoulder circumference measurement and estimation of the level of pain will be repeated. Also blood will be taken from a vein and complete blood count will be repeated. During the postoperative period, the amount and type of analgesic drugs administered and the length of hospitalization will be monitored.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • - rotator cuff tear

排除标准

  • allergy to tranexamic acid, paracetamol (acetaminophen), ketoprofen, tramadol or metamizole sodium
  • deep vein thrombosis
  • congenital thrombophilia
  • coagulopathy
  • thromboembolic events within the previous 12 months
  • stroke or acute coronary syndrome within the previous 3 months
  • renal failure
  • liver cirrhosis
  • glaucoma or retinal vascular disorder
  • chronic treatment with anticoagulant or antiplatelet therapy
  • uncontrolled hypertension (systolic blood pressure > 180 mmHg)

研究组 & 干预措施

Tranexamic acid injectable product

Experimental

Patients from the experimental group will receive 10 minutes before the procedure 1 g of tranexamic acid in 100 ml of saline intravenously

干预措施: Tranexamic Acid Injectable Product (Drug)

Placebo

Placebo Comparator

Patients from the control group will receive 10 minutes before the procedure 100 ml sterile saline intravenously

干预措施: Placebo (Drug)

结局指标

主要结局

Visual Clarity on Endoscope Screen During Shoulder Arthroscopy (Intraoperative)

时间窗: From skin incision to final suture (intraoperative period), assessed every 15 minutes, up to 135 minutes

The operating surgeon evaluated intraoperative visual clarity using the Visual Analog Scale for visibility (VAS-V), ranging from 0 (worst visual clarity) to 10 (best visual clarity), at 15-minute intervals during shoulder arthroscopy. At each assessment time point, the endoscope screen was simultaneously photographed. The surgeon was blinded to group allocation. Visual clarity assessments performed from skin incision up to 135 minutes of surgery were included in the analysis. For each participant, all intraoperative VAS-V measurements within this period were averaged to obtain a single mean intraoperative visibility score. Higher scores indicate better visual clarity.

次要结局

  • Independent Assessor Visibility Rating (VAS)(From skin incision to final suture (intraoperative period), up to 135 minutes; image assessments performed after completion of surgery)
  • Interobserver Agreement of Independent Assessors for Arthroscopic Visibility Ratings (VAS)(After completion of surgery, following blinded assessment of standardized intraoperative arthroscopic images obtained from skin incision to final suture.)
  • Comparison of Arthroscopic Visibility Ratings Between the Operating Surgeon and Independent Assessors (VAS)(From skin incision to final suture (intraoperative period), assessed every 15 minutes, up to 135 minutes; independent image evaluations performed after completion of surgery)
  • Concentration of Hemoglobin in Waste Irrigation Fluid (mg/100 mL)(From skin incision to final suture (intraoperative period))
  • Number of Irrigation Pump Pressure-boost Events(From skin incision to final suture (intraoperative period))
  • Total Irrigation Fluid Volume Used (L)(From skin incision to final suture (intraoperative period))
  • Intraoperative Mean Arterial Pressure (MAP), mmHg(From skin incision to final suture (intraoperative period))
  • Duration of Surgery (Minutes)(From skin incision to final suture (intraoperative period))
  • Intraoperative Blood Loss (mL)(From skin incision to final suture (intraoperative period))
  • Total Perioperative Blood Loss (mL)(From preoperative baseline (measured 1 day before surgery) to postoperative day 2)
  • Postoperative (Hidden) Blood Loss (mL)(From completion of surgery (final suture) to postoperative day 2)
  • Perioperative Drop in Hemoglobin (g/dL)(From preoperative baseline (measured 1 day before surgery) to postoperative day 2)
  • Change in Upper-arm Circumference (cm) as Marker of Swelling(From preoperative baseline (measured 1 day before surgery) to postoperative day 2)
  • Postoperative Pain (VAS, 0-10)(From postoperative day 1 to postoperative day 2)
  • Total Postoperative Analgesic Consumption (mg)(From completion of surgery (final suture) until hospital discharge (postoperative inpatient period), up to 7 days)
  • Length of Hospital Stay (Days)(From surgery until hospital discharge (postoperative inpatient period))

研究者

发起方
Nikola Matejcic
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Nikola Matejcic

Principal investigator

Clinic for Orthopedics Lovran

研究点 (1)

Loading locations...

相似试验